Nefecon FDA Approval Status
FDA Approved: No
Brand name: Nefecon
Generic name: budesonide
Company: Calliditas Therapeutics AB
Treatment for: Nephropathy
Nefecon (budesonide) is an oral, targeted release formulation of the approved anti-inflammatory corticosteroid budesonide in development for the treatment of primary IgA nephropathy (IgAN).
Development Timeline for Nefecon
|Mar 15, 2021||Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.